A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Insomnia Disorder
Latest Information Update: 24 Apr 2024
At a glance
- Drugs YZJ-1139 (Primary)
- Indications Insomnia
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Haiyan Pharmaceutical Technology
Most Recent Events
- 24 Apr 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 17 Apr 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 17 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.